15 results
8-K
EX-99.2
PYXS
Pyxis Oncology Inc
21 Mar 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
7:44am
and target engagement Stronger target binding to human Siglec-15 versus competitor (NC318) More potent reversal of Siglec-15-mediated T cell suppression ex
8-K/A
EX-99.1
PYXS
Pyxis Oncology Inc
27 Oct 23
Index to Consolidated Financial Statements
4:34pm
”).
We also entered into a letter agreement (the “Engagement Agreement”) with the Placement Agent, pursuant to which the Placement Agent agreed to serve
424B3
c616mrt
30 Jun 23
Prospectus supplement
4:05pm
S-4/A
my0luir8mqtpqv7 jc
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
fdpclfznf 6pv
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
425
lneqp2owhwurhln3ggb
24 May 23
Business combination disclosure
7:05am
425
1nj6lupj skpcvy
24 May 23
Business combination disclosure
7:03am
8-K
EX-2.1
d8rq2
24 May 23
Pyxis Oncology to Acquire Apexigen
6:59am
DEF 14A
9i8wb0hvrpnws93
28 Apr 22
Definitive proxy
4:33pm
10-K
y41uv4n2g 7j2
29 Mar 22
Annual report
7:36am
S-1/A
EX-10.14
yloufwnnkf1z9w
30 Sep 21
IPO registration (amended)
9:11pm
- Prev
- 1
- Next